We are a purpose-driven team, passionate about developing innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions for underserved mental health disorders, beginning with postpartum depression (PPD). Leveraging our team’s extensive experience in neuroscience drug development, we are advancing RE104, a patented, clinical-stage drug candidate designed as a safe, fast-acting, short duration therapy for patients with underserved mental health disorders. RE104, the only 4-OH-DiPT prodrug in clinical development, will be evaluated in the RECONNECT Phase 2 clinical trial as a potential treatment for PPD that could provide rapid symptom relief and durable efficacy.

In addition to advancing our lead candidate, RE104, we are developing our RE200 series of drug discovery candidates for application in more chronic treatment paradigms and indications. These therapies are structurally similar to classic psychedelics and designed to have selective potency at the target serotonin 2A receptor (5HT2AR) and are devoid of off-target 5HT2B receptor agonism.


Greg Mayes

Greg Mayes

President & Chief Executive Officer

Edward Smith

Edward Smith

Chief Financial Officer

Nathan Bryson, PhD

Dr. Nathan Bryson

Chief Scientific Officer

Robert Alexander

Dr. Robert Alexander

Chief Medical Officer


Beatrix Taylor, MSc, RAC

Senior Vice President, Clinical Development & Regulatory Affairs


Mark Theeuwes

Chief Operating Officer


Dr. Anita H. Clayton is the Wilford W. Spradlin Professor and Chair of Psychiatry and Neurobehavioral Sciences and Professor of Clinical Obstetrics and Gynecology at the University of Virginia. She has published over 200 peer-reviewed papers and was named to the 2019-2020 Best Doctors in America list. She has focused her clinical practice and research on major depressive disorder, mood disorders associated with reproductive-life events in women, sexual dysfunction, and sexual disorders. Anita is recognized as an international leader in female sexual disfunction and has served on numerous international and domestic boards, including: as Past President of the International Society for the Study of Women’s Sexual Health (ISSWSH); Vice-Chair for Women’s Sexual Health for the 3rd and 4th International Consultation on Sexual Medicine (ICSM); World Health Organization (WHO) advisory committee on the ICD-11 chapter, Conditions Related to Sexual Health; and Scientific Program Committee for the International Society for Sexual Medicine (ISSM). She has served on the board of directors for the American Society for Clinical Psychopharmacology (ASCP)where she served as president and as Program Committee Co-Chair.

Dr. Kristina Deligiannidis is the Director of Women’s Behavioral Health at Zucker Hillside Hospital, Northwell Health and a Professor of Psychiatry, Molecular Medicine and Obstetrics and Gynecology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Dr. Deligiannidis is also the Medical Director for Reproductive Psychiatry for the perinatal psychiatry access program, Project TEACH, funded by the NY State Office of Mental Health. As a reproductive psychiatrist, she has expertise in treating women with mood and anxiety disorders linked to the menstrual cycle, perinatal and perimenopausal periods. Dr. Deligiannidis received her medical degree from and completed her psychiatry residency and chief residency in psychopharmacology research at the University of Massachusetts Chan Medical School. Prior to and during medical school she trained in neuroscience research at the NIH. After residency she completed additional research training in behavioral endocrinology and experimental therapeutics at the NIH and in neuroimaging at the Martinos Center for Biomedical Imaging at MGH. Dr. Deligiannidis is a nationally recognized leader in the field of perinatal depression and in novel therapeutics research.

Dr. Sheryl Kingsberg is the chief of the division of behavioral medicine at MacDonald Women’s Hospital/University Hospitals Cleveland Medical Center and Professor in Reproductive Biology, Urology and Psychiatry at Case Western Reserve University. Her areas of clinical specialization include female sexual disorders, menopause, pregnancy and postpartum mood disorders, and psychological aspects of infertility. Dr. Kingsberg’s primary research interests are in treatments for female sexual disorders, genitourinary syndrome of menopause (GSM) and reproductive mental health. She is an Associate Editor for Sexual Medicine Reviews and sits on the editorial boards of the journals Menopause and Climacteric. She has over 100 peer-reviewed publications and numerous book chapters and has co-edited a multidisciplinary textbook on treating female sexual disorders. Dr. Kingsberg is a past president of The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. She currently serves as the Advocacy Committee Chair for both of these organizations.

Dr. Manish Agarwal brings an extensive background and experience that spans medicine, engineering, philosophy, and ethics to his role as CEO of Sunstone Therapies. Driven by a deep interest in healing, Manish is particularly passionate about whole person healing and the transformative potential of psychedelic therapies. Manish previously held the position of Co-Director of Clinical Research at Maryland Oncology Hematology, where he dedicated 15 years to the care of cancer patients. He completed a fellowship at the National Cancer Institute, National Institutes of Health, and his residency at Georgetown University Medical Center.

Dr. Matthew W. Johnson is The Susan Hill Ward Endowed Professor of at Johns Hopkins. Working with psychedelics since 2004, he has played a role in the modern-day revival of psychedelic research. He has published research on psychedelics and mystical experience, personality change, tobacco smoking cessation, cancer distress treatment, and depression treatment. In 2021 he received as principal investigator the first grant in about 50 years from the US government to administer a classic psychedelic as a treatment, specifically psilocybin for tobacco addiction. He is also known for his expertise in behavioral economics, addiction, sexual risk behavior, and research with a wide variety of drug classes. He has been Interviewed by Anderson Cooper on 60 Minutes, the New York Times, the Washington Post, the Wall Street Journal, CNN, NPR, Fox News, BBC, the Lex Fridman Podcast, the Huberman Lab Podcast, Big Think and Michael Pollan.

Dr. Mark Pollack is an accomplished and influential biopharma and healthcare executive, with a proven track record in CNS research strategy, development and medical affairs, as well as of building and transforming medical organizations, focusing on growth through innovation. He was formerly the SVP for Global Medical Affairs at Sage Therapeutics and CMO for Neuroscience of Myriad Genetics. Prior to moving to industry, Mark was Chairman of the Dept. of Psychiatry and Behavioral Sciences at Rush University Medical Center and Director of its Mental Health Service Line. Prior to Rush, Dr. Pollack directed the Center for Anxiety and Traumatic Stress Disorders and was Professor of Psychiatry at Massachusetts General Hospital (MGH) and Harvard Medical School. He established a groundbreaking research career supported by over 25 years of continuous federal funding, focused on a multidisciplinary neuroscientific approach to anxiety, PTSD, affective disorders and substance abuse. Dr. Pollack is a past President of the Anxiety and Depression Association of America and former Chair of its Scientific Advisory Board. Mark established centers of excellence at MGH and Rush to provide state of the art care for veterans and their families affected by PTSD. Dr. Pollack has over 500 publications and has lectured widely around the world. He is a summa cum laude graduate of the University of Virginia, earned his M.D. at New Jersey Medical School and completed a residency and fellowship in psychiatry at MGH and Harvard Medical School.